Molluscum Publications

Molluscum Disease State

• Hebert AA, Bhatia N, Del Rosso JQ. Molluscum Contagiosum: Epidemiology, Considerations, Treatment Options, and Therapeutic Gaps. J Clin Aesthet Dermatol. 2023 Aug;16(8 Suppl 1):S4-S11. PMID: 37636018; PMCID: PMC10453394.
• Chao YC, Ko MJ, Tsai WC, Hsu LY, Wu HY. Comparative efficacy of treatments for molluscum contagiosum: A systematic review and network meta-analysis. J Dtsch Dermatol Ges. 2023 Jun;21(6):587-597. doi: 10.1111/ddg.15063. Epub 2023 May 18. PMID: 37199262.
• Han H, Smythe C, Yousefian F, Berman B. Molluscum Contagiosum Virus Evasion of Immune Surveillance: A Review. J Drugs Dermatol. 2023 Feb 1;22(2):182-189. doi: 10.36849/JDD.7230. PMID: 36745361.
• Lacarrubba F, Micali G, Trecarichi AC, Quattrocchi E, Monfrecola G, Verzì AE. New Developing Treatments for Molluscum Contagiosum. Dermatol Ther (Heidelb). 2022 Dec;12(12):2669-2678. doi: 10.1007/s13555-022-00826-7. Epub 2022 Oct 14. PMID: 36239905; PMCID: PMC9674806.
• Silverman RF, Shinder R. Molluscum Contagiosum. N Engl J Med. 2022 Feb 10;386(6):582. doi: 10.1056/NEJMicm2113300. PMID: 35139276.
• Silverberg NB. Pediatric molluscum: an update. Cutis. 2019 Nov;104(5):301-305;E1;E2. PMID: 31886783.
• Phan S, Wyant C, Huynh C, Joaquin C, Hassan O. Efficacy of topical treatments for molluscum contagiosum in randomized controlled trials. Clin Dermatol. 2021 Nov-Dec;39(6):1005-1013. doi: 10.1016/j.clindermatol.2021.07.002. Epub 2021 Jul 16. PMID: 34920817.
• Eichenfield L, Hebert A, Mancini A, Rosen T, Weiss J. Therapeutic Approaches and Special Considerations for Treating Molluscum Contagiosum. J Drugs Dermatol. 2021 Nov 1;20(11):1185-1190. doi: 10.36849/jdd.6383. PMID: 34784125.
• Hanson D, Diven DG. Molluscum contagiosum. Dermatol Online J. 2003 Mar;9(2):2. PMID: 12639455.
• Kantor J. This Month in JAAD International: April 2025: Options of molluscum contagiosum management. J Am Acad Dermatol. 2025;92(4):704. doi:10.1016/j.jaad.2025.01.062.
• Verma KK, Burningham KM, Tyring SK. Innovation in Warts and Molluscum: An Updated Comprehensive Review. Dermatol Clin. 2025;43(1):95-102. doi:10.1016/j.det.2024.08.007
• Cartwright M, Maeda-Chubachi T, Enloe C, Stripling S. A retrospective claims analysis of US pediatricians prescribing practices for the treatment of Molluscum Contagiosum. Open J Pediatr Child Health. 2024; 9(1): 045-049.
• Cartwright M, Maeda-Chubachi T, Enloe C, Stripling S, Hebert A. How are pediatricians treating molluscum contagiosum? results from in-depth interviews. Open J Pediatr Child Health. 2024; 9(1): 040-044. DOI: https://dx.doi.org/10.17352/ojpch.000056

BERDAZIMER (Zelsuvmi)

• Ward BM, Riccio DA, Cartwright M, Maeda-Chubachi T. The Antiviral Effect of Berdazimer Sodium on Molluscum Contagiosum Virus Using a Novel In Vitro Methodology. Viruses. 2023 Nov 30;15(12):2360. doi: 10.3390/v15122360. PMID: 38140601; PMCID: PMC10747301
• Sugarman JL, Hebert A, Browning JC, Paller AS, Stripling S, Green LJ, Cartwright M, Enloe C, Wells N, Maeda-Chubachi T. Berdazimer gel for molluscum contagiosum: An integrated analysis of 3 randomized controlled trials. J Am Acad Dermatol. 2023 Oct 5:S0190-9622(23)02890-6. doi: 10.1016/j.jaad.2023.09.066. Epub ahead of print. PMID: 37804936.
• Pera Calvi I, R Marques I, Cruz SA, Mesquita YLL, Padrao EMH, Souza RM, Brown A, Caçador DGV, Poppe LM, Lopes Almeida Gomes L. Safety and efficacy of topical nitric oxide-releasing berdazimer gel for molluscum contagiosum clearance: A systematic review and meta-analysis of randomized controlled trials. Pediatr Dermatol. 2023 Nov-Dec;40(6):1060-1063. doi: 10.1111/pde.15419. Epub 2023 Sep 18. PMID: 37721050.
• Cartwright M, Enloe C, Stripling S, Maeda-Chubachi T. Pharmacokinetic Profile, Safety, and Tolerability of Topical Berdazimer Gel, 10.3% in Patients With Molluscum Contagiosum. J Drugs Dermatol. 2022 Oct 1;21(10):1104-1110. doi: 10.36849/JDD.6938. PMID: 36219053.
• Browning JC, Enloe C, Cartwright M, Hebert A, Paller AS, Hebert D, Kowalewski EK, Maeda-Chubachi T. Efficacy and Safety of Topical Nitric Oxide-Releasing Berdazimer Gel in Patients With Molluscum Contagiosum: A Phase 3 Randomized Clinical Trial. JAMA Dermatol. 2022 Aug 1;158(8):871-878. doi: 10.1001/jamadermatol.2022.2721. PMID: 35830173; PMCID: PMC9280611.
• Hebert AA, Siegfried EC, Durham T, de León EN, Reams T, Messersmith E, Maeda-Chubachi T. Efficacy and tolerability of an investigational nitric oxide-releasing topical gel in patients with molluscum contagiosum: A randomized clinical trial. J Am Acad Dermatol. 2020 Apr;82(4):887-894. doi:10.1016/j.jaad.2019.09.064. Epub 2019 Oct 3. PMID: 31586600.
• Banerjee NS, Moore DW, Wang HK, Broker TR, Chow LT. NVN1000, a novel nitric oxide-releasing compound, inhibits HPV-18 virus production by interfering with E6 and E7 oncoprotein functions. Antiviral Res. 2019 Oct;170:104559. doi: 10.1016/j.antiviral.2019.104559. Epub 2019 Jul 15. PMID: 31319090.
• Tyring SK, Rosen T, Berman B, Stasko N, Durham T, Maeda-Chubachi T. A Phase 2 Controlled Study of SB206, a Topical Nitric Oxide-Releasing Drug for Extragenital Wart Treatment. J Drugs Dermatol. 2018 Oct 1;17(10):1100-1105. PMID: 30365591.
• Dabbs W, Chamberlin S. Berdazimer (Zelsuvmi) for the Treatment of Molluscum Contagiosum. Am Fam Physician. 2025;111(3):263-264.
• Keam SJ. Berdazimer Topical Gel, 10.3%: First Approval. Drugs. 2024;84(3):363-368. doi:10.1007/s40265-024-02012-9
• Paller AS, Green LJ, Silverberg N, et al. Berdazimer gel for molluscum contagiosum in patients with atopic dermatitis. Pediatr Dermatol. Published online February 27, 2024. doi:10.1111/pde.15575
• Browning JC, Cartwright M, Thorla I Jr, Martin SA, Olayinka-Amao O, Maeda- Chubachi T. A Patient-Centered Perspective of Molluscum Contagiosum as Reported by B-SIMPLE4 Clinical Trial Patients and Caregivers: Global Impression of Change and Exit Interview Substudy Results. Am J Clin Dermatol. 2023 Jan;24(1):119-133. doi: 10.1007/s40257-022-00733-9. Epub 2022 Oct 26. PMID: 36287306; PMCID: PMC9870829.
• Kawashima, M, et al. The safety and tolerability of berdazimer gel, 10.3% in Japanese patients with molluscum contagiosum. JAAD Int. Oct 4, 2024. https://www.jaadinternational.org/article/S2666-3287(24)00153-6/fulltext

VP-102-Cantheradin (YCANTH)

• Gupta AK, Mann A, Vincent K, Abramovits W. YCANTH™  (Cantharidin) Topical Solution. Skinmed. 2023 Nov 10;21(5):360-363. PMID: 37945366.
• Eichenfield LF, Kwong P, Gonzalez ME, Yan A, D’Arnaud P, Burnett P, Olivadoti M. Safety and Efficacy of VP-102 (Cantharidin, 0.7% w/v) in Molluscum Contagiosum by Body Region: <i>Post hoc</i> Pooled Analyses from Two Phase III Randomized Trials. J Clin Aesthet Dermatol. 2021 Oct;14(10):42-47. PMID: 34976290; PMCID: PMC8711618.
• Eichenfield LF, Siegfried E, Kwong P, McBride M, Rieger J, Glover D, Willson C, Davidson M, Burnett P, Olivadoti M. Pooled Results of Two Randomized Phase III Trials Evaluating VP-102, a Drug-Device Combination Product Containing Cantharidin 0.7% (w/v) for the Treatment of Molluscum Contagiosum. Am J Clin Dermatol. 2021 Mar;22(2):257-265. doi: 10.1007/s40257-020-00570-8. Epub 2021 Feb 18. PMID: 33599960; PMCID: PMC7973914.
• Niazi S, Brabec B, Anschutz L, Willson C, Davidson M, Burnett P. A Phase 2 Open-Label Study to Evaluate VP-102 for the Treatment of Molluscum Contagiosum. J Drugs Dermatol. 2021 Jan 1;20(1):70-75. doi: 10.36849/JDD.5626. PMID: 33400412.
• Eichenfield LF, McFalda W, Brabec B, Siegfried E, Kwong P, McBride M, Rieger J, Willson C, Davidson M, Burnett P. Safety and Efficacy of VP-102, a Proprietary, Drug-Device Combination Product Containing Cantharidin, 0.7% (w/v), in Children and Adults With Molluscum Contagiosum: Two Phase 3 Randomized Clinical Trials. JAMA Dermatol. 2020 Dec 1;156(12):1315-1323. doi: 10.1001/jamadermatol.2020.3238. PMID: 32965495; PMCID: PMC7512131.
• Ogilvie-Turner K, Goldman RD. Cantharidin for molluscum contagiosum. Can Fam Physician. 2020 Jun;66(6):419-420. PMID: 32532721; PMCID: PMC7292508.
• Del Rosso JQ, Kircik L. Topical Cantharidin in the Management of Molluscum Contagiosum: Preliminary Assessment of an Ether-free, Pharmaceutical-grade Formulation. J Clin Aesthet Dermatol. 2019 Feb;12(2):27-30. Epub 2019 Feb 1. PMID: 30881580; PMCID: PMC6415708.